壳聚糖碘治疗CINⅠ伴高危HPV感染的疗效观察
|
摘要
目的:探讨壳聚糖碘治疗宫颈上皮内瘤变Ⅰ(CINⅠ)伴人乳头状瘤病毒(HPV)感染的临床疗效及安全性,为临床应用提供参考。方法:选取2014年10月~2015年6月科室确诊CINⅠ伴HPV感染的患者100例,随机分为治疗组和对照组,各50例,治疗组使用壳聚糖碘治疗,对照组未用药物治疗,观察治疗组的不良反应情况,对比两组患者治疗高危HPV感染转阴情况,所得数据采用SPSS16.0进行分析。结果:治疗组3个月及6个月HPV转阴率分别为74.0%、78.0%,对照组3个月及6个月HPV转阴率分别为48.0%、62.0%,差异有统计学意义(P<0.05),治疗组患者无严重不良反应发生。结论:壳聚糖碘治疗CIN1伴HPV感染疗效确切、不良反应小,值得临床推广应用。
Objective:To investigate clinical efficacy and safety of Chitosan-iodine in treatment of high-risk human papillomaviras infection in patients with cervical intraepithelial neoplasia Ⅰ(CIN Ⅰ).Methods:A total of 100 patients diagnosed with CIN Ⅰ and cervical high-risk HPV infection during Oct.2014 to Jun.2015 were randomly divided into group treatment and group control with 50 cases in each group.Women of group treatment were received Chitosan-iodine,group control did not received any medication.The therapeutic results for high-risk HPV infection change to negative patients were compared between the two groups and adverse reactions were observed.Data obtained were analyzed using the software SPSS16.0.Results:The high-risk HPV infection change to negative rate were 74.0% within three month and 78.0% within six month respectively in group treatment,48.0% within three month and 62.0% within six month respectively in group control the difference was significant(P<0.05).There were no serious adverse reactions were observed in group treatment.Conclusion:Treatment of Chitosan-iodine for CIN Ⅰ with high-risk human papillomaviras infection in patients resulted in significant efficacy and few adverse reactions,which was worthy of clinical application.
Objective:To investigate clinical efficacy and safety of Chitosan-iodine in treatment of high-risk human papillomaviras infection in patients with cervical intraepithelial neoplasia Ⅰ(CIN Ⅰ).Methods:A total of 100 patients diagnosed with CIN Ⅰ and cervical high-risk HPV infection during Oct.2014 to Jun.2015 were randomly divided into group treatment and group control with 50 cases in each group.Women of group treatment were received Chitosan-iodine,group control did not received any medication.The therapeutic results for high-risk HPV infection change to negative patients were compared between the two groups and adverse reactions were observed.Data obtained were analyzed using the software SPSS16.0.Results:The high-risk HPV infection change to negative rate were 74.0% within three month and 78.0% within six month respectively in group treatment,48.0% within three month and 62.0% within six month respectively in group control the difference was significant(P<0.05).There were no serious adverse reactions were observed in group treatment.Conclusion:Treatment of Chitosan-iodine for CIN Ⅰ with high-risk human papillomaviras infection in patients resulted in significant efficacy and few adverse reactions,which was worthy of clinical application.
引文
[1]Guido,R.,N.M.Lonky,and J.Diedrich,Secondary prevention of cervical cancer part 3:evidence-based management of women with cervical intraepithelial neoplasia.Clin Obstet Gynecol,2014,57(2):302-315.
[2]Peralta-Zaragoza,O.,J.Deas,C.Gomez-Ceron,et al.,HPVBased Screening,Triage,Treatment,and Followup Strategies in the Management of Cervical Intraepithelial Neoplasia.Obstet Gynecol Int,2013.2013:912780.
[3]van der Heijden,E.,A.D.Lopes,A.Bryant,et al.,Follow-up strategies after treatment(large loop excision of the transformation zone(LLETZ))for cervical intraepithelial neoplasia(CIN):Impact of human papillomavirus(HPV)test.Cochrane Database Syst Rev,2015,1:CD010757.
[4]郎景和.子宫颈上皮内瘤变的诊断与治疗[J].中华妇产科杂志,2001(5):4-6.
[5]钟辉,刘锦钰,龙璐雯.人乳头状瘤病毒和EB病毒在子宫颈上皮内瘤变中的表达[J].蚌埠医学院学报,2012(7):765-768.
[6]许莉莉,赵仁峰.宫颈上皮内瘤变与高危型HPV感染的研究进展[J].中国临床新医学,2015(4):381-383.
[7]徐思慧,曹保利.治疗性HPV DNA疫苗的研究进展[J].基础医学与临床,2015(3):421-424.
[8]杨琳,张金玲,张立杰,等.4种疗法对宫颈上皮内瘤变Ⅰ级的治疗效果比较[J].山东医药,2013(11):59-60.
[9]王芳宇,张启锋,何丽芳,等.壳聚糖碘液体外抗人单纯疱疹病毒2型的作用[J].中国皮肤性病学杂志,2011(2):101-103.
[10]麻攀,谭成玉,白雪芳,等.几丁质、壳聚糖及其降解产物对巨噬细胞的作用[J].细胞与分子免疫学杂志,2008(10):1027-1028+1031.
[11]柴红军,田伟.几丁质、壳聚糖在抗肿瘤方面的应用[J].沈阳医学院学报,2013(1):51-52+55.
[12]胡逸君.壳碘宫颈栓治疗宫颈糜烂并发HPV感染的临床观察[J].浙江临床医学,2014(12):1940-1941.
[2]Peralta-Zaragoza,O.,J.Deas,C.Gomez-Ceron,et al.,HPVBased Screening,Triage,Treatment,and Followup Strategies in the Management of Cervical Intraepithelial Neoplasia.Obstet Gynecol Int,2013.2013:912780.
[3]van der Heijden,E.,A.D.Lopes,A.Bryant,et al.,Follow-up strategies after treatment(large loop excision of the transformation zone(LLETZ))for cervical intraepithelial neoplasia(CIN):Impact of human papillomavirus(HPV)test.Cochrane Database Syst Rev,2015,1:CD010757.
[4]郎景和.子宫颈上皮内瘤变的诊断与治疗[J].中华妇产科杂志,2001(5):4-6.
[5]钟辉,刘锦钰,龙璐雯.人乳头状瘤病毒和EB病毒在子宫颈上皮内瘤变中的表达[J].蚌埠医学院学报,2012(7):765-768.
[6]许莉莉,赵仁峰.宫颈上皮内瘤变与高危型HPV感染的研究进展[J].中国临床新医学,2015(4):381-383.
[7]徐思慧,曹保利.治疗性HPV DNA疫苗的研究进展[J].基础医学与临床,2015(3):421-424.
[8]杨琳,张金玲,张立杰,等.4种疗法对宫颈上皮内瘤变Ⅰ级的治疗效果比较[J].山东医药,2013(11):59-60.
[9]王芳宇,张启锋,何丽芳,等.壳聚糖碘液体外抗人单纯疱疹病毒2型的作用[J].中国皮肤性病学杂志,2011(2):101-103.
[10]麻攀,谭成玉,白雪芳,等.几丁质、壳聚糖及其降解产物对巨噬细胞的作用[J].细胞与分子免疫学杂志,2008(10):1027-1028+1031.
[11]柴红军,田伟.几丁质、壳聚糖在抗肿瘤方面的应用[J].沈阳医学院学报,2013(1):51-52+55.
[12]胡逸君.壳碘宫颈栓治疗宫颈糜烂并发HPV感染的临床观察[J].浙江临床医学,2014(12):1940-1941.